Literature DB >> 3756934

Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline.

D F Bajorin, G J Bosl, N W Alcock, D Niedzwiecki, E Gallina, B Shurgot.   

Abstract

Nephrotoxicity, the dose-limiting toxicity of cis-diamminedichloroplatinum(II) (CDDP), is ameliorated when administered in hypertonic saline with normal saline hydration. To determine whether the diminished nephrotoxicity is associated with alteration of the pharmacokinetics of CDDP, we examined the pharmacokinetics of free and total platinum, platinum renal excretion, and urine electrolytes in patients given CDDP in hypertonic saline and in patients given CDDP in a conventional manner. The pharmacokinetics of free and total platinum for equal doses of CDDP were similar regardless of the vehicle of administration and the method of hydration. CDDP given in a vehicle of high chloride concentration with normal saline hydration resulted in a statistically significant increase in both urine volume and chloruresis compared to the conventional regimen. The decreased nephrotoxicity associated with administration of CDDP in hypertonic saline with saline diuresis may be related to increased chloruresis, urinary volume, or a combination of both, but did not appear to be related to an alteration in the pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3756934

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Determination of cis-diamminedichloroplatinum (II) in plasma proteins and hemoglobin of cancer patients.

Authors:  R Mustonen; P Hietanen; S Leppälä; M Takala; K Hemminki
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

2.  A Review of Hydrogen Sulfide Synthesis, Metabolism, and Measurement: Is Modulation of Hydrogen Sulfide a Novel Therapeutic for Cancer?

Authors:  Xu Cao; Lei Ding; Zhi-Zhong Xie; Yong Yang; Matthew Whiteman; Philip K Moore; Jin-Song Bian
Journal:  Antioxid Redox Signal       Date:  2018-06-29       Impact factor: 8.401

3.  Metabolomics for the early detection of cisplatin-induced nephrotoxicity.

Authors:  Takeshi Ezaki; Shin Nishiumi; Takeshi Azuma; Masaru Yoshida
Journal:  Toxicol Res (Camb)       Date:  2017-08-29       Impact factor: 3.524

Review 4.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

5.  Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures.

Authors:  F Doz; M E Berens; D V Dougherty; M L Rosenblum
Journal:  J Neurooncol       Date:  1991-08       Impact factor: 4.130

6.  Long-term pharmacokinetic behavior of platinum after cisplatin administration.

Authors:  E Gamelin; P Allain; P Maillart; A Turcant; R Delva; A Lortholary; F Larra
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Alteration of N6-Methyladenosine RNA Profiles in Cisplatin-Induced Acute Kidney Injury in Mice.

Authors:  Can-Ming Li; Ming Li; Wen-Bo Zhao; Zeng-Chun Ye; Hui Peng
Journal:  Front Mol Biosci       Date:  2021-07-09

8.  Two cases of cisplatin-induced permanent renal failure following neoadjuvant chemotherapy for esophageal cancer.

Authors:  Tomohiko Sasaki; Satoru Motoyama; Atsushi Komatsuda; Hiroyuki Shibata; Yusuke Sato; Kei Yoshino; Akiyuki Wakita; Hajime Saito; Akira Anbai; Mario Jin; Yoshihiro Minamiya
Journal:  Int J Surg Case Rep       Date:  2016-01-18

9.  Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients.

Authors:  F E de Jongh; R N van Veen; S J Veltman; R de Wit; M E L van der Burg; M J van den Bent; A S Th Planting; W J Graveland; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

10.  Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.

Authors:  J Ma; J Verweij; H J Kolker; H E van Ingen; G Stoter; J H Schellens
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.